Return to study ST000433 main page
MB Sample ID: SA021809
Local Sample ID: | sample47 |
Subject ID: | SU000454 |
Subject Type: | Human |
Subject Species: | Homo sapiens |
Taxonomy ID: | 9606 |
Species Group: | Human |
Select appropriate tab below to view additional metadata details:
Subject:
Subject ID: | SU000454 |
Subject Type: | Human |
Subject Species: | Homo sapiens |
Taxonomy ID: | 9606 |
Species Group: | Human |
Factors:
Local Sample ID | MB Sample ID | Factor Level ID | Level Value | Factor Name |
---|---|---|---|---|
sample47 | SA021809 | FL005330 | Mixed DLB and AD | Group |
Collection:
Collection ID: | CO000448 |
Collection Summary: | All blood samples in the Mayo Clinic ADRC are collected from nonfasting participants in the sitting position in a clinical laboratory. Serum tubes (red-top) are drawn first, followed by EDTA plasma tubes. Blood is drawn from the median cubital vein with a 21 g needle and typically centrifuged at 2000 g for 10 minutes at 4°C. The serum and plasma are aliquoted into 0.5 mL and stored in a −80°C freezer until use. None of the aliquots were thawed before being pulled to measure the sphingolipids and fatty acids. We have previously shown that long-term storage, up to 38 years, in long-term −80°C freezers does not affect sphingolipid levels [26]. |
Sample Type: | Blood |
Treatment:
Treatment ID: | TR000468 |
Treatment Summary: | All individuals were enrolled in the Mayo Clinic Alzheimer's Disease Research Center (ADRC) and donated their brain to the Neuropathology Core. Eligibility criteria for the proposed study included an autopsy report and available blood at the last study visit before death. Standardized methods for sampling and neuropathologic examination were performed according to the third report of the DLB consortium (CDLB) [20], [21] and the Consortium to Establish a Registry for Alzheimer's Disease guidelines [22]. Braak neurofibrillary tangle (NFT) stage was determined based on the distribution of NFTs assessed with Bielschowsky silver stain [23]. A consensus clinical diagnosis was determined at each study visit by a panel of neurologists, neuropsychologists, and nurses who reviewed all patient information including neuropsychological results, activities of daily living, and the Clinical Dementia Rating scale. The diagnosis of dementia was based on DSM-III-R criteria [24]. We identified the following four groups: (1) Cognitively normal-normal pathology [CN, n = 21]. These individuals had no LBs, had low-likelihood AD according to the National Institute of Aging (NIA)-Reagan Criteria [25], and were cognitively normal as of their last study visit. (2) High-likelihood DLB [n = 13]. These individuals met criteria for high-likelihood DLB according to the CDLB, had Braak NFT stage ≤ IV, low to intermediate-likelihood AD, and a diagnosis of dementia as of the last study visit. Twelve patients had diffuse LB and one had transitional LB. (3) Intermediate-likelihood DLB (n = 17). These individuals had both DLB and AD pathologies. They had transitional (n = 14) or diffuse (n = 3) LBs, met criteria for intermediate-likelihood DLB according to the CDLB, had Braak NFT stage ≥ IV, intermediate to high-likelihood AD, and a diagnosis of dementia as of the last study visit. (4) Alzheimer's disease pathology (AD, n = 18). These individuals had high (n = 16) or intermediate (n = 2) likelihood AD according to NIA-Reagan criteria, had Braak NFT stage ≥ IV, no LBs, and had a diagnosis of probable AD dementia. Given our previous report that plasma ceramides increase with age and are higher in women [26], we frequency matched the four groups by sex and also by age. |
Sample Preparation:
Sampleprep ID: | SP000461 |
Sampleprep Summary: | The lipids were extracted from 200 μL of plasma after the addition of internal standards. |
Combined analysis:
Analysis ID | AN000683 |
---|---|
Analysis type | MS |
Chromatography type | Reversed phase |
Chromatography system | Thermo TSQ Quantum Ultra |
Column | Waters Acquity BEH C18 (150 x 2.1mm,1.7um) |
MS Type | ESI |
MS instrument type | Triple quadrupole |
MS instrument name | Thermo Quantum Ultra |
Ion Mode | POSITIVE |
Units | micromolar |
Chromatography:
Chromatography ID: | CH000495 |
Chromatography Summary: | The targeted sphingolipid and fatty acid analyses were conducted by the Mayo Clinic Metabolomics Core. Electrospray ionization mass spectrometry was used to quantify plasma ceramides, sphinganine, sphingosine, sphingosine-1-phosphate (S1P), monohexosylceramides, and free fatty acids. The lipids were extracted from 200 μL of plasma after the addition of internal standards. The extracts were measured against a standard curve on the Thermo TSQ Quantum Ultra mass spectrometer (West Palm Beach, FL) coupled with a Waters Acquity UPLC system (Milford, MA) and quantified in μM units. |
Instrument Name: | Thermo TSQ Quantum Ultra |
Column Name: | Waters Acquity BEH C18 (150 x 2.1mm,1.7um) |
Chromatography Type: | Reversed phase |
MS:
MS ID: | MS000609 |
Analysis ID: | AN000683 |
Instrument Name: | Thermo Quantum Ultra |
Instrument Type: | Triple quadrupole |
MS Type: | ESI |
Ion Mode: | POSITIVE |